Cargando…
Mesenchymal stem cells and management of COVID-19 pneumonia
Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. G...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147223/ https://www.ncbi.nlm.nih.gov/pubmed/32296777 http://dx.doi.org/10.1016/j.medidd.2020.100019 |
_version_ | 1783520378605273088 |
---|---|
author | Metcalfe, Su M. |
author_facet | Metcalfe, Su M. |
author_sort | Metcalfe, Su M. |
collection | PubMed |
description | Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame. |
format | Online Article Text |
id | pubmed-7147223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71472232020-04-10 Mesenchymal stem cells and management of COVID-19 pneumonia Metcalfe, Su M. Med Drug Discov Article Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame. Published by Elsevier B.V. 2020-03 2020-03-19 /pmc/articles/PMC7147223/ /pubmed/32296777 http://dx.doi.org/10.1016/j.medidd.2020.100019 Text en Crown Copyright © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Metcalfe, Su M. Mesenchymal stem cells and management of COVID-19 pneumonia |
title | Mesenchymal stem cells and management of COVID-19 pneumonia |
title_full | Mesenchymal stem cells and management of COVID-19 pneumonia |
title_fullStr | Mesenchymal stem cells and management of COVID-19 pneumonia |
title_full_unstemmed | Mesenchymal stem cells and management of COVID-19 pneumonia |
title_short | Mesenchymal stem cells and management of COVID-19 pneumonia |
title_sort | mesenchymal stem cells and management of covid-19 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147223/ https://www.ncbi.nlm.nih.gov/pubmed/32296777 http://dx.doi.org/10.1016/j.medidd.2020.100019 |
work_keys_str_mv | AT metcalfesum mesenchymalstemcellsandmanagementofcovid19pneumonia |